Primary Care Reports – October 1, 2004
October 1, 2004
View Issues
-
Pharmacology Watch: Linking COX-2 Inhibitors and Cardiovascular Event Risk
A new, and as of yet unpublished study, has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events. -
Clinical Briefs in Primary Care Supplement